.Pharmacolibrary.Drugs.C_CardiovascularSystem.C02L_AntihypertensivesAndDiureticsInCombination.C02LB01_MethyldopaLevorotatoryAn.MethyldopaLevorotatoryAn .Pharmacolibrary.Drugs.C_CardiovascularSystem.C02L_AntihypertensivesAndDiureticsInCombination.C02LB01_MethyldopaLevorotatoryAn.MethyldopaLevorotatoryAn| name: | MethyldopaLevorotatoryAndDiuretics | |
| ATC code: | C02LB01 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 130 | ml/min |
| other parameters in model implementation | ||
Methyldopa (levorotatory) is an antihypertensive agent in the centrally acting antiadrenergic class, often used in combination with diuretics for the management of moderate to severe hypertension. It acts as a centrally acting alpha-2 adrenergic agonist, reducing peripheral vascular resistance. This combination was commonly used in the past, particularly in pregnancy-induced hypertension, but methyldopa is less frequently a first-line agent today.
Estimated pharmacokinetic parameters for methyldopa (levorotatory) co-administered with diuretics in adult patients, as direct published PK data for this specific combination is not available.
Gonçalves, PVB, et al., & Lanchote, VL (2020). A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. Journal of clinical pharmacology 60(12) 1655–1661. DOI:10.1002/jcph.1681 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32562572